BIOMAT Database Logo BIOMAT Database Logo

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. 1990

Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
Royal Ottawa Hospital, Ottawa, Ontario, Canada.

The efficacy and side-effect profile for three dose ranges of remoxipride were compared with haloperidol in 242 schizophrenic inpatients in 13 centres. All patients were in a productive phase of schizophrenia according to DSM-III criteria. Relative efficacy of low dose (30-90 mg daily) vs middle dose (120-240 mg daily) vs high dose (300-600 mg daily) was compared with the standard dose of haloperidol (15-45 mg daily), as were the side effects. It was concluded that the therapeutic efficacy of remoxipride was comparable to that of haloperidol for acute episodes of schizophrenia; that the low dose range was significantly less effective than the higher ranges; that there was a clear advantage of remoxipride over haloperidol with respect to incidence and severity of extrapyramidal symptoms. The general safety profile of remoxipride as assessed from clinical chemistry, haematology, and cardiovascular variables suggests that remoxipride in the dose ranges studied can be used safely for the treatment of schizophrenic patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002170 Canada The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia.
September 1991, Pharmacopsychiatry,
Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia.
January 1990, Acta psychiatrica Scandinavica. Supplementum,
Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group.
July 1997, Journal of psychiatry & neuroscience : JPN,
Y D Lapierre, and N P Nair, and G Chouinard, and A G Awad, and B Saxena, and B Jones, and D J McClure, and D Bakish, and P Max, and R Manchanda
A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia.
March 1996, Psychopharmacology,
Copied contents to your clipboard!